Literature DB >> 21122034

Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate.

D Wen1, L Qing, G Harrison, E Golub, S O Akintoye.   

Abstract

OBJECTIVES: Bisphosphonates commonly used to treat osteoporosis, Paget's disease, multiple myeloma, hypercalcemia of malignancy and osteolytic lesions of cancer metastasis have been associated with bisphosphonate-associated jaw osteonecrosis (BJON). The underlying pathogenesis of BJON is unclear, but disproportionate bisphosphonate concentration in the jaw has been proposed as one potential etiological factor. This study tested the hypothesis that skeletal biodistribution of intravenous bisphosphonate is anatomic site-dependent in a rat model system.
MATERIALS AND METHODS: Fluorescently labeled pamidronate was injected intravenously in athymic rats of equal weights followed by in vivo whole body fluorimetry, ex vivo optical imaging of oral, axial, and appendicular bones and ethylenediaminetetraacetic acid bone decalcification to assess hydroxyapatite-bound bisphosphonate.
RESULTS: Bisphosphonate uptake and bisphosphonate released per unit calcium were similar in oral and appendicular bones but lower than those in axial bones. Hydroxyapatite-bound bisphosphonate liberated by sequential acid decalcification was the highest in oral, relative to axial and appendicular bones (P < 0.05).
CONCLUSIONS: This study demonstrates regional differences in uptake and release of bisphosphonate from oral, axial, and appendicular bones of immune deficient rats.
© 2010 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122034      PMCID: PMC3071450          DOI: 10.1111/j.1601-0825.2010.01772.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  24 in total

Review 1.  Bisphosphonates: mechanisms of action.

Authors:  G A Rodan; H A Fleisch
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

2.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

3.  Influence of pyrophosphate on the exchange of calcium and phosphate ions on hydroxyapatite.

Authors:  A Jung; S Bisaz; P Bartholdi; H Fleisch
Journal:  Calcif Tissue Res       Date:  1973

4.  In vivo near-infrared fluorescence imaging of osteoblastic activity.

Authors:  A Zaheer; R E Lenkinski; A Mahmood; A G Jones; L C Cantley; J V Frangioni
Journal:  Nat Biotechnol       Date:  2001-12       Impact factor: 54.908

5.  Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.

Authors:  Frieder Bauss; Sigrid Lalla; Richard Endele; Ludwig A Hothorn
Journal:  J Rheumatol       Date:  2002-10       Impact factor: 4.666

Review 6.  Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption.

Authors:  A Ezra; G Golomb
Journal:  Adv Drug Deliv Rev       Date:  2000-08-31       Impact factor: 15.470

7.  Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats.

Authors:  J H Lin; I W Chen; D E Duggan
Journal:  Drug Metab Dispos       Date:  1992 Jul-Aug       Impact factor: 3.922

Review 8.  Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.

Authors:  Matthew R Allen
Journal:  Cells Tissues Organs       Date:  2008-08-13       Impact factor: 2.481

9.  Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate.

Authors:  D Stefanik; J Sarin; T Lam; L Levin; P S Leboy; S O Akintoye
Journal:  Oral Dis       Date:  2008-07       Impact factor: 3.511

Review 10.  New insights into the molecular mechanisms of action of bisphosphonates.

Authors:  Michael J Rogers
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  20 in total

Review 1.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

2.  Zoledronate induces bisphosphonate-related osteonecrosis of the jaw in osteopenic sheep.

Authors:  Pit J Voss; Martin J Stoddart; Anke Bernstein; Rainer Schmelzeisen; Katja Nelson; Vincent Stadelmann; Thomas Ziebart; Philipp J Poxleitner
Journal:  Clin Oral Investig       Date:  2015-04-07       Impact factor: 3.573

3.  Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea.

Authors:  Woo Seok Kang; Shuting Sun; Kim Nguyen; Boris Kashemirov; Charles E McKenna; S Adam Hacking; Alicia M Quesnel; William F Sewell; Michael J McKenna; David H Jung
Journal:  Otol Neurotol       Date:  2015-07       Impact factor: 2.311

Review 4.  Osteonecrosis of the Jaw-a Bone Site-Specific Effect of Bisphosphonates.

Authors:  Jenny A F Vermeer; Greetje A P Renders; Vincent Everts
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

5.  Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry.

Authors:  Brianne S Raccor; Jianxun Sun; Ross F Lawrence; Lei Li; Hai Zhang; Martha J Somerman; Rheem A Totah
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-07-27       Impact factor: 3.205

Review 6.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 7.  Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors.

Authors:  Jason T Wan; Douglas M Sheeley; Martha J Somerman; Janice S Lee
Journal:  Bone Res       Date:  2020-03-11       Impact factor: 13.567

8.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

9.  In vivo imaging of bone using a deep-red fluorescent molecular probe bearing multiple iminodiacetate groups.

Authors:  Kara M Harmatys; Erin L Cole; Bradley D Smith
Journal:  Mol Pharm       Date:  2013-10-22       Impact factor: 4.939

10.  Equilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.

Authors:  Akishige Hokugo; Shuting Sun; Sil Park; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2012-12-04       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.